Mercer Global Advisors
IBB icon

Mercer Global Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Mercer Global Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.32M Buy
13,732
+945
+7% +$162K ﹤0.01% 1124
2025
Q4 		$2.16M Sell
12,787
-274
-2% -$44.5K ﹤0.01% 1069
2025
Q3 		$1.89M Sell
13,061
-1,715
-12% -$234K ﹤0.01% 1061
2025
Q2 		$1.87M Sell
14,776
-1,333
-8% -$164K ﹤0.01% 915
2025
Q1 		$2.06M Buy
16,109
+446
+3% +$60.5K ﹤0.01% 831
2024
Q4 		$2.07M Buy
15,663
+1,605
+11% +$226K 0.01% 817
2024
Q3 		$2.04M Buy
14,058
+602
+4% +$87.1K ﹤0.01% 771
2024
Q2 		$1.85M Sell
13,456
-402
-3% -$53.7K 0.01% 742
2024
Q1 		$1.91M Buy
13,858
+216
+2% +$29.5K 0.01% 742
2023
Q4 		$1.85M Sell
13,642
-1,313
-9% -$160K 0.01% 765
2023
Q3 		$1.83M Sell
14,955
-443
-3% -$56.3K 0.01% 740
2023
Q2 		$1.96M Sell
15,398
-1,471
-9% -$191K 0.01% 727
2023
Q1 		$2.18M Buy
16,869
+102
+0.6% +$13.4K 0.01% 650
2022
Q4 		$2.2M Buy
16,767
+5,906
+54% +$763K 0.01% 666
2022
Q3 		$1.27M Buy
10,861
+2,789
+35% +$346K 0.01% 756
2022
Q2 		$950K Sell
8,072
-775
-9% -$92K 0.01% 870
2022
Q1 		$1.15M Buy
8,847
+1,511
+21% +$197K 0.01% 842
2021
Q4 		$1.12M Buy
7,336
+569
+8% +$88.1K 0.01% 833
2021
Q3 		$1.09M Buy
6,767
+2,968
+78% +$499K 0.01% 823
2021
Q2 		$622K Buy
3,799
+982
+35% +$151K ﹤0.01% 1040
2021
Q1 		$424K Buy
2,817
+1,176
+72% +$187K ﹤0.01% 1148
2020
Q4 		$249K Sell
1,641
-710
-30% -$101K ﹤0.01% 1149
2020
Q3 		$318K Sell
2,351
-620
-21% -$84.1K ﹤0.01% 938
2020
Q2 		$406K Buy
2,971
+342
+13% +$43.6K 0.01% 751
2020
Q1 		$283K Sell
2,629
-439
-14% -$50.5K 0.01% 829
2019
Q4 		$370K Sell
3,068
-291
-9% -$32.5K 0.01% 838
2019
Q3 		$334K Buy
3,359
+561
+20% +$58.7K 0.01% 855
2019
Q2 		$305K Buy
2,798
+489
+21% +$52K 0.01% 872
2019
Q1 		$258K Buy
+2,309
New +$253K 0.01% 876

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Mercer Global Advisors's IBB Position: Q1 2026 in Review

Mercer Global Advisors increased its iShares Biotechnology ETF (IBB) stake by 7.4% in Q1 2026, buying an estimated $162K and bringing the position to 13,732 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1124.

Mercer Global Advisors first reported a position in IBB in Q1 2019 and has held it in 29 quarters since. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Mercer Global Advisors held 13,732 shares of iShares Biotechnology ETF worth $2.32M as of Q1 2026.
  • Mercer Global Advisors bought 945 iShares Biotechnology ETF shares in Q1 2026, an estimated $162K.
  • iShares Biotechnology ETF made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #1124 holding.
  • Mercer Global Advisors first reported a position in iShares Biotechnology ETF in Q1 2019 and has held it in 29 quarters since.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.